Defining the role of endogenous glucagon-like peptide-1 (GLP-1) in the glycaemic, triglyceride and energy expenditure responses to fat in patients with Type 2 Diabetes (T2D) using Galvus (vildagliptin) and the GLP-1 receptor antagonist exendin (9-39)
Phase of Trial: Phase IV
Latest Information Update: 11 Jul 2016
At a glance
- Drugs Vildagliptin (Primary) ; Exendin 9
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- 08 Jul 2016 Planned End Date changed from 12 Dec 2016 to 31 Jul 2018.
- 08 Jul 2016 Status changed from not yet recruiting to recruiting.
- 28 Nov 2014 New trial record